Palmitoylated prolactin-releasing peptide treatment had neuroprotective but not anti-obesity effect in fa/fa rats with leptin signaling disturbances.

ABSTRACT:

Background/objective

Anorexigenic palmitoylated prolactin-releasing peptide (palm¹¹-PrRP) is able to act centrally after peripheral administration in rat and mouse models of obesity, type 2 diabetes mellitus and/or neurodegeneration. Functional leptin and intact leptin signaling pathways are necessary for the body weight reducing and glucose tolerance improving effect of palm¹¹-PrRP. We have previously shown that palm¹¹-PrRP31 had glucose-lowering properties but not anti-obesity effect in Koletsky rats with leptin signaling disturbances, so improvements in glucose metabolism appear to be completely independent of leptin signaling. The purpose of this study was to describe relationship between metabolic and neurodegenerative pathologies and explore i

SUBMITTER: Mrazikova L 

PROVIDER: S-EPMC9119973 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature